<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23889" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Renal Lymphoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bokhari</surname>
            <given-names>Maria R.</given-names>
          </name>
          <aff>Tulane Hospital , Louisiana</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rana</surname>
            <given-names>Usman I.</given-names>
          </name>
          <aff>King Edward Medical University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bokhari</surname>
            <given-names>Syed Rizwan A.</given-names>
          </name>
          <aff>Tulane Un, Un Med Center New Orleans</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Maria Bokhari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Usman Rana declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Syed Rizwan Bokhari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23889.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Renal involvement in lymphoma is commonly in the presence of widespread nodal or extranodal lymphoma. This is classified as secondary renal lymphoma (SRL). Rarely, lymphoma may involve the kidneys alone without evidence of disease elsewhere; this presentation is termed primary renal lymphoma (PRL). Although the diagnosis of renal lymphoma can be challenging, an awareness of the spectrum of imaging findings can help to differentiate lymphoma from other renal malignancies, such as renal cell carcinoma (RCC), and can lead to appropriate recommendations for biopsy. This activity reviews the pathophysiology of renal lymphoma and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of lymphoma of the kidney.</p></list-item><list-item><p>Review the presentation of a renal lymphoma.</p></list-item><list-item><p>Summarize the treatment options for renal lymphoma.</p></list-item><list-item><p>Explain the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by lymphoma of the kidney.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23889&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23889">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23889.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Renal involvement in lymphoma is commonly in the presence of widespread nodal or extranodal lymphoma. This&#x000a0;is classified as secondary renal lymphoma (SRL). Rarely, lymphoma may involve the kidneys alone without evidence of disease elsewhere; this presentation is termed <italic toggle="yes">primary renal lymphoma</italic>&#x000a0;(PRL). Although the diagnosis of renal lymphoma can be challenging, an awareness of the spectrum of imaging findings can help to differentiate lymphoma from other renal malignancies, such as renal cell carcinoma (RCC), and can lead to appropriate recommendations for biopsy. An accurate diagnosis is critical because renal lymphoma is treated by chemotherapy whereas RCC is typically managed by surgery or ablation.<xref ref-type="bibr" rid="article-23889.r1">[1]</xref><xref ref-type="bibr" rid="article-23889.r2">[2]</xref><xref ref-type="bibr" rid="article-23889.r3">[3]</xref>Renal lymphoma is commonly secondary to lymphomatous infiltration of the kidneys in systemic disseminated lymphoma&#x000a0;and advanced stage IV disease while renal lymphoma arising&#x000a0;primarily&#x000a0;in the renal parenchyma is a rarely described entity. Primary renal lymphoma comprises only 0.7% of extranodal lymphomas.<xref ref-type="bibr" rid="article-23889.r4">[4]</xref><xref ref-type="bibr" rid="article-23889.r5">[5]</xref></p>
      </sec>
      <sec id="article-23889.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Renal involvement in autopsy cases is secondary to non-Hodgkin disease in 30% to 60% of cases.&#x000a0;Immunocompromised patients with uncontrolled Epstein-Barr virus proliferation, organ transplantation, patients undergoing chemotherapeutic therapy, patients with HIV infection, or ataxia-telangiectasia patients are at increased risk. Primary renal lymphoma is of Hodgkin-type arising in hilar nodes or renal parenchyma form&#x000a0;only less than 1 % of renal lymphoma. Association of the tumor has been found with chronic inflammatory and infectious diseases like Sjogren, systemic lupus erythematosus, chronic pyelonephritis, and Epstein-Barr virus infections.<xref ref-type="bibr" rid="article-23889.r6">[6]</xref><xref ref-type="bibr" rid="article-23889.r7">[7]</xref></p>
      </sec>
      <sec id="article-23889.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>While renal lymphoma has autopsy incidence of 30% to 60% in lymphoma patients, actual CT diagnosis incidence is approximately 5%. The kidneys are the most common abdominal organ affected by non-Hodgkin lymphoma.&#x000a0;Involvement of the kidneys in primary renal lymphoma is rare (less than 1%). It is mostly seen in middle to advanced age. It forms about 0.7% of the extranodal lymphomas in North America. The bilateral presentation is seen in 10% to 20% of the cases.</p>
      </sec>
      <sec id="article-23889.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The kidneys are the most common abdominal organ affected by systemic lymphoma according to several studies. Renal involvement is most common with B-cell lymphoma, and the majority are intermediate or high-grade lymphomas including Burkitt and histiocytic varieties.&#x000a0;Gross macroscopy reveals fleshy or firm yellow, tan, or gray tumors that are 1 to 20 cm. The pathogenesis of primary renal lymphoma is dubious as the normal kidney does not have any lymphoid tissue.&#x000a0;Puente Duanay hypothesized that pre-existing inflammatory processes recruit lymphoid cells into renal parenchyma and an&#x000a0;untimely oncogenic event takes place to complete the multistep process of oncogenesis. The renal capsule is rich in lymphatics, and it has been suggested that the tumor penetrates the parenchyma from the capsule, subcapsular tissue, or the renal sinus with subsequent invasion of the renal parenchyma. Tumor proliferation initiates in the interstitium and the adjacent nephrons and collecting ducts, and blood vessels act as a framework for tumor growth. An infiltrative growth pattern results in preservation of the parenchymal structures and renal contour. Consequently, detection of renal involvement becomes difficult and can easily be missed on histopathology. As lymphomatous tumors enlarge, the surrounding renal parenchyma is compressed and displaced causing the formation of solitary or more commonly multiple nodular masses. Uneven infiltrative growth can result in extension beyond the renal capsule into the perinephric space, mimicking primary renal neoplasms. Continued growth may ultimately cause replacement of the whole renal parenchymal architecture.</p>
      </sec>
      <sec id="article-23889.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Renal lymphoma&#x000a0;is commonly seen as a part of the spectrum of multi-systemic; however, it may seldom be seen as a primary disease.&#x000a0;It usually presents in middle-aged persons although half of the cases may be clinically silent.&#x000a0;Presenting symptoms include flank pain, weight loss, fever, night sweats, palpable abdominal mass, hematuria, and deranged renal function usually seen as elevated serum creatinine.</p>
        <p>Primary renal lymphoma is an infiltrative tumor that grows without disruption of structure or function. However, the most common presentation of primary renal lymphoma is acute renal failure, flank pain, and mass. The cause for renal failure is somewhat ambiguous, but several theories have been postulated including lymphomatous infiltration of the parenchyma, hypercalcemia due to vitamin D overproduction by the lymphomatous mass or ureteral, and vascular or tubular compression by the lesion.</p>
      </sec>
      <sec id="article-23889.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Renal Function Studies</bold>
</p>
        <p>Laboratory studies to assess renal function include blood urea nitrogen (BUN) and creatinine. Although clinical evidence of renal involvement with lymphoma is only seen in 2% to 14 %of patients, an elevated serum creatinine is reported in 26% to 56%. An elevated BUN or creatinine level may indicate bilateral ureteral obstruction subsequent to massive retroperitoneal lymph nodes or as a adverse effect of nephrotoxic chemotherapeutic agents.<xref ref-type="bibr" rid="article-23889.r8">[8]</xref><xref ref-type="bibr" rid="article-23889.r9">[9]</xref><xref ref-type="bibr" rid="article-23889.r10">[10]</xref></p>
        <p>
<bold>Renal Biopsy</bold>
</p>
        <p>The diagnosis of primary renal lymphoma requires biopsy in most cases as imaging findings are nonspecific. Although fine-needle aspiration is a useful technique, core tissue biopsy with flow cytometry and immunohistochemical staining is recommended as it has a higher diagnostic accuracy according to several studies.</p>
        <p>With regard to secondary renal lymphoma (SRL), renal biopsy is usually not required in the presence of disseminated disease. However, it is reported that patients with lymphoma have a higher incidence of renal cell carcinoma (RCC) than the general population. Differentiating SRL presenting as a solitary mass (typically hypovascular) from clear cell RCC (mostly hypervascular) on imaging may be straightforward. Nonetheless, other histologic subtypes of RCC, like papillary and chromophobe RCCs, can also appear hypovascular on imaging, making it harder to differentiate from SRL. In such cases, a renal biopsy may be validated.</p>
        <p>
<bold>Imaging</bold>
</p>
        <p>There are several patterns of lymphomatous involvement of kidneys; the most common on imaging is multiple parenchymal nodular masses of variable size, typically 1 to 4.5 cm in diameter. This presentation is seen in approximately 50 to 60% of cases. The lesions are usually bilateral, but unilateral renal presentation can also be seen. The second most common pattern of involvement constitutes a contiguous extension to the kidneys or perinephric space from large retroperitoneal nodal masses (seen in 25% to 30% of cases).</p>
        <p>Renal lymphoma presenting as a solitary mass is encountered in 10% to 25% of patients. On non-enhanced CT scan lymphomatous mass is slightly more hyperattenuating than the surrounding normal renal parenchyma. At contrast-enhanced CT, the mass is hypovascular and characteristically demonstrates minimal enhancement. This feature is invaluable in differentiating renal lymphoma from RCC, which mostly manifests moderate to avid enhancement in the arterial phase. Isolated perinephric lymphoma is rarely seen (less than 10% of cases). Contrast-enhanced CT scans are important for demonstrating a ring of homogeneous perinephric tissue which encases the normal parenchyma, with contrast-enhanced causing any significant renal dysfunction. Diffuse renal enlargement without distortion of the reniform shape of the kidneys or formation of any discrete masses presents in 6% to 19% of cases. Nephromegaly is almost always bilateral. If both kidneys are extensively infiltrated, acute renal failure. Contrast-enhanced CT demonstrates heterogeneous enhancement of the kidneys, loss of the normal corticomedullary differential enhancement, encasement and deformation of the pevicalyceal system, and infiltration of the renal sinus fat. Alternatively, the renal parenchyma is replaced by&#x000a0;poorly defined low-attenuation lesions. The collecting system is encased and stretched instead of being displaced. The sonographic picture of infiltrative renal lymphoma is globular enlargement of the kidneys with heterogeneous echotexture and effacement of renal sinus.</p>
        <p>
<bold>Nuclear Imaging</bold>
</p>
        <p>Gallium-67 citrate has been used for diagnosing and staging lymphoma. This radioisotope concentrates in lymphoma. and is taken up by lymphomatous tissue in the kidneys. It also is&#x000a0;concentrated in the inflammatory masses of the kidney. The degree of sensitivity increases in case of high grade lymphoma.18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) scanning has been commonly used for staging and follow-up after treatment. The use of another agent, technetium-99m (Tc)-labeled antibody (LL2), has been advocated in imaging and staging lymphomas, especially in cases of low-grade lymphoma.</p>
      </sec>
      <sec id="article-23889.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Differentiating renal lymphoma from other renal masses is crucial as well as challenging, especially in cases of unilateral lesions that mimic renal carcinomas both radiologically as well as pathologically. The standard management of a renal mass is radial or partial nephrectomy. However, a patient with renal lymphoma is treated with systemic chemotherapy.</p>
        <p>Surgery or systemic chemotherapy, with or without radiotherapy, is a widely-used treatment for primary renal lymphoma. The prognosis of patients affected by primary renal lymphoma is grave, despite the absence of disseminated disease.&#x000a0;For bilateral renal lymphoma, systemic chemotherapy using a CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen is the treatment of choice; this preserves the organ function, but the subsequent prognosis is poor because although chemotherapy usually improves the renal function. The few cases reported in the&#x000a0;literature show increased mortality because of rapid relapse or infections occurring from neutropenia. Alternatively, bilateral nephrectomy invariably leads to the permanent need for hemodialysis. Overall survival rate and long-term disease-free interval are relatively better when surgery and chemotherapy are combined.</p>
      </sec>
      <sec id="article-23889.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Abscess</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Acute pyelonephritis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Angiomyolipoma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Bladder cancer</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chronic pyelonephritis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Non-Hodgkin lymphoma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Renal adenoma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Renal cyst</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Renal infarction</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Wilms disease</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23889.s10" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Lymphoma of the kidney may be primary or secondary, but in both cases making a diagnosis is not easy. The disorder is best managed by an interprofessional team that includes the pathologist, radiologist, urologist, oncologist, radiation specialist and a team of specialty nurses. To differentiate lymphoma from other renal cancers usually requires a biopsy. Once diagnosed, the treatment is chemotherapy plus radiation. The prognosis of these patients depend on whether the lymphoma is primary or secondary. With advances in treatment, most patients have improved survival but complications of therapy often can be life-threatening.<xref ref-type="bibr" rid="article-23889.r11">[11]</xref><xref ref-type="bibr" rid="article-23889.r12">[12]</xref></p>
      </sec>
      <sec id="article-23889.s11">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23889&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23889">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/renal-lymphoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23889">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23889/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23889">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-23889.s12">
        <fig id="article-23889.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Bilateral multinodular renal presentation of disseminated non Hodgkin disease seen on post contrast CT scan Contributed by Jinnah Hospital; Lahore, Pakistan</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="IMG-20170329-WA0006" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-23889.s13">
        <title>References</title>
        <ref id="article-23889.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of Action for HDAC Inhibitors-Insights from Omics Approaches.</article-title>
            <source>Int J Mol Sci</source>
            <year>2019</year>
            <month>Apr</month>
            <day>01</day>
            <volume>20</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">30939743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23889.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stanescu</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Acharya</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Pediatric Renal Neoplasms:: MR Imaging-Based Practical Diagnostic Approach.</article-title>
            <source>Magn Reson Imaging Clin N Am</source>
            <year>2019</year>
            <month>May</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>279</fpage>
            <page-range>279-290</page-range>
            <pub-id pub-id-type="pmid">30910098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23889.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Roberti</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Petroni</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reniero</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cicora</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Renal Medullary Carcinoma: a Report of the Current Literature.</article-title>
            <source>Curr Urol Rep</source>
            <year>2019</year>
            <month>Jan</month>
            <day>17</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <pub-id pub-id-type="pmid">30656488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23889.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Amanam</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rahmanuddin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mambetsariev</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Reckamp</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vora</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Salgia</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma.</article-title>
            <source>Am J Clin Oncol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>42</volume>
            <issue>4</issue>
            <fpage>337</fpage>
            <page-range>337-344</page-range>
            <pub-id pub-id-type="pmid">30741758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23889.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Velvet</surname>
                <given-names>AJJ</given-names>
              </name>
              <name>
                <surname>Bhutani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Papachristos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dwivedi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Picton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Augustine</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Morton</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A single-center experience of post-transplant lymphomas involving the central nervous system with a review of current literature.</article-title>
            <source>Oncotarget</source>
            <year>2019</year>
            <month>Jan</month>
            <day>11</day>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>437</fpage>
            <page-range>437-448</page-range>
            <pub-id pub-id-type="pmid">30728897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23889.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sakr</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Baiocchi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Hemminger</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Erdheim Chester disease in a patient with Burkitt lymphoma: a case report and review of literature.</article-title>
            <source>Diagn Pathol</source>
            <year>2018</year>
            <month>Nov</month>
            <day>24</day>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>94</fpage>
            <pub-id pub-id-type="pmid">30474563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23889.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsuchimoto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Masutani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Omoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Okumi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Okabe</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nishiki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ota</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nakano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tsuruya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kitazono</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ishida</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tanabe</surname>
                <given-names>K</given-names>
              </name>
              <collab>Japan Academic Consortium of Kidney Transplantation (JACK) Investigators</collab>
            </person-group>
            <article-title>Kidney transplantation for treatment of end-stage kidney disease after haematopoietic stem cell transplantation: case series and literature review.</article-title>
            <source>Clin Exp Nephrol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>561</fpage>
            <page-range>561-568</page-range>
            <pub-id pub-id-type="pmid">30584654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23889.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ishioka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ohtake</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tamai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Oki</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Matsui</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mochida</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Moriya</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hidaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Intravascular lymphoma forming massive aortic tumors complicated with sarcoidosis and focal segmental glomerulosclerosis: a case report and literature review.</article-title>
            <source>BMC Nephrol</source>
            <year>2018</year>
            <month>Oct</month>
            <day>29</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>300</fpage>
            <pub-id pub-id-type="pmid">30373554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23889.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uppal</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Monga</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vernace</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Mehtabdin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Bijol</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Jhaveri</surname>
                <given-names>KD</given-names>
              </name>
            </person-group>
            <article-title>Kidney diseases associated with Waldenstr&#x000f6;m macroglobulinemia.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2019</year>
            <month>Oct</month>
            <day>01</day>
            <volume>34</volume>
            <issue>10</issue>
            <fpage>1644</fpage>
            <page-range>1644-1652</page-range>
            <pub-id pub-id-type="pmid">30380110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23889.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ouyang</surname>
                <given-names>ZZ</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>QH</given-names>
              </name>
              <name>
                <surname>Ouyang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>JX</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>QX</given-names>
              </name>
              <name>
                <surname>Zhan</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>T-cell lymphoma with rhabdomyolysis: case report and literature review.</article-title>
            <source>Braz J Med Biol Res</source>
            <year>2018</year>
            <volume>51</volume>
            <issue>11</issue>
            <fpage>e6278</fpage>
            <pub-id pub-id-type="pmid">30304093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23889.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benoni</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Eloranta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ekbom</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wilczek</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Smedby</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Survival among solid organ transplant recipients diagnosed with cancer compared to nontransplanted cancer patients-A nationwide study.</article-title>
            <source>Int J Cancer</source>
            <year>2020</year>
            <month>Feb</month>
            <day>01</day>
            <volume>146</volume>
            <issue>3</issue>
            <fpage>682</fpage>
            <page-range>682-691</page-range>
            <pub-id pub-id-type="pmid">30919451</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23889.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mrdenovic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heffer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhau</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>LWK</given-names>
              </name>
            </person-group>
            <article-title>Targeting Burkitt lymphoma with a tumor cell-specific heptamethine carbocyanine-cisplatin conjugate.</article-title>
            <source>Cancer</source>
            <year>2019</year>
            <month>Jul</month>
            <day>01</day>
            <volume>125</volume>
            <issue>13</issue>
            <fpage>2222</fpage>
            <page-range>2222-2232</page-range>
            <pub-id pub-id-type="pmid">30840322</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
